HBSAG LOSS WITH TENOFOVIR DISOPROXIL FUMARATE PLUS PEGINTERFERON ALFA-2A IN CHRONIC HEPATITIS B: LONG-TERM RESULTS OF A GLOBAL RANDOMIZED CONTROLLED TRIAL

被引：0

作者：

Ahn, S. -H. ^{[1
]}

Marcellin, P. ^{[2
]}

Ma, X. ^{[3
]}

Caruntu, F. ^{[4
]}

Tak, W. Y. ^{[5
]}

Elkhashab, M. ^{[6
]}

Chuang, W. -L. ^{[7
]}

Tabak, F. ^{[8
]}

Mehta, R. ^{[9
]}

Petersen, J. ^{[10
]}

Corsa, A. ^{[11
]}

Martins, E. B. ^{[11
]}

Yee, L. J. ^{[11
]}

Dinh, P. ^{[11
]}

Subramanian, G. Mani ^{[11
]}

Buti, M. ^{[12
]}

Gaeta, G. ^{[13
]}

Papatheodoridis, G. ^{[14
]}

Flisiak, R. ^{[15
]}

Chan, H. L. Y. ^{[16
]}

机构：

[1] Yonsei Univ, Coll Med, Seoul, South Korea

[2] Univ Paris Diderot, Hop Beaujon, Clichy, France

[3] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA

[4] Natl Inst Infect Dis Prof Dr Matei Bals, Bucharest, Romania

[5] Kyungpook Natl Univ, Sch Med, Daegu, South Korea

[6] Toronto Liver Ctr, Toronto, ON, Canada

[7] Kaohsiung Med Univ, Chung Ho Mem Hosp, Kaohsiung, Taiwan

[8] Istanbul Univ Cerrahpasa, Fac Med, Istanbul, Turkey

[9] Liver Clin, Surat, India

[10] Univ Hamburg, Hamburg, Germany

[11] Gilead Sci, Foster City, CA USA

[12] Hosp Univ Vall dHebron, Barcelona, Spain

[13] Univ Naples 2, Naples, Italy

[14] Univ Athens, Sch Med, Athens, Greece

[15] Med Univ Bialystok, Bialystok, Poland

[16] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

10.1016/S0168-8278(16)00924-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

FRI-256

引用

页码：S524 / S525

页数：2

共 50 条

[31] HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
Al Ashgar, Hamad
Peedikayil, Musthafa C.
Al Quaiz, Mohammed
Al Sohaibani, Fahad
Al Fadda, Abdulrahman
Khan, Mohammed Q.
Thoralsson, Einar
Al Thawadi, Sahar
Al Jedai, Ahmed
Al Kahtani, Khalid
SAUDI JOURNAL OF GASTROENTEROLOGY, 2017, 23 (03): : 190 - 198
[32] LONG-TERM, HIGH-DOSE PEGINTERFERON ALFA-2A IS AN EFFECTIVE TREATMENT FOR CHRONIC HEPATITIS D
Heller, Theo
Rotman, Yaron
Haynes-Williams, Vanessa
Kleiner, David E.
Ghany, Marc G.
Liang, T. Jake
Hoofnagle, Jay H.
HEPATOLOGY, 2009, 50 (04) : 734A - 734A
[33] ADDITION OF PEGINTERFERON ALFA-2a INCREASES HBsAg DECLINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL. (PAS STUDY)
Farag, Mina S.
Fung, Scott K.
Van Campenhout, Margo
Van Erpecum, Karel J.
Wong, David K. H.
Boonstra, Andre
Verhey, Elke
De Man, Robert A.
Liem, Kin Seng
Hansen, Bettina E.
Janssen, Harry L. A.
HEPATOLOGY, 2019, 70 : 127A - 128A
[34] Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B
Bahri Abayli
Cansu Abayl?
Genco Gencdal
World Journal of Gastrointestinal Pharmacology and Therapeutics, 2021, 12 (02) : 32 - 39
[35] Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain
Turnes, Juan
Romero-Gomez, Manuel
Planas, Ramon
Sola, Ricard
Garcia-Samaniego, Javier
Diago, Moises
Crespo, Javier
Calleja, Jose Luis
Rubio-Terres, Carlos
Ventayol, Pere
GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (09): : 555 - 564
[36] BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
Takkenberg, B.
Zaaijer, H.
Weegink, C.
Terpstra, V.
Dijkgraaf, M.
Jansen, P.
Janssen, H.
Beld, M.
Reesink, H.
JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
[37] Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers
Chen, Xue-Bing
Liu, Fei-Fei
Shu, Fu-Li
Liu, Jian-Ying
Yang, Jia-Hong
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (05)
[38] INTERIM RESULTS OF A DOUBLE-BLIND, RANDOMIZED PHASE 2 STUDY OF THE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE, AND ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B SUBJECTS WITH DECOMPENSATED LIVER DISEASE
Liaw, Yun-Fan
Lee, Chuan-Mo
Akarca, Ulus S.
George, Papatheodoridis V.
Wong, Florence
Chang, Ting-Tsung
Horban, Andrzej
Wang, Chia C.
Kwan, Peter
Buti, Maria
Prieto, Martin
Berg, Thomas
Kitrinos, Kathryn M.
Sorbel, Jeff
Mondou, Elsa
Frederick, David
Rousseau, Franck
Schiff, Eugene R.
HEPATOLOGY, 2009, 50 (04) : 409A - 410A
[39] Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
Lee, I-Cheng
Su, Chien-Wei
Lan, Keng-Hsin
Lin, Han-Chieh
Hou, Ming-Chih
Huang, Yi-Hsiang
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E471 - E471
[40] Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial
Iida-Ueno, Ayako
Enomoto, Masaru
Kozuka, Ritsuzo
Tamori, Akihiro
Kawada, Norifumi
JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (07) : 1295 - 1300

← 1 2 3 4 5 →